跳至主要内容
临床试验/NCT07335536
NCT07335536招募中不适用

The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.

Diansan Su3 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2025年10月20日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
400
试验地点
3
主要终点
Incidence of Hypoxia

研究概览

简要总结

Hypoxia is the most common adverse reaction during sedation outside the operating room.Exploring novel drug combinations to reduce the incidence of hypoxia during sedation in patients undergoing transvaginal oocyte retrieval procedures enhances patient safety and lowers perioperative adverse event rates. This multicenter, prospective, randomized, controlled clinical study will compare the hypoxia incidence rate of the remimazolam-alfentanil combination against the commonly used propofol-alfentanil combination.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Subjects aged 18 to 50 years planning to undergo painless oocyte retrieval
  • Subjects classified as American Society of Anesthesiologists (ASA) physical status I-II

排除标准

  • Subjects with contraindications to general anesthesia, acute or severe cardiovascular disease history, acute upper respiratory infection, chronic obstructive pulmonary disease (COPD), asthma attacks, or uncontrolled hypertension
  • Subjects with alcohol abuse
  • Subjects with severe hepatic or renal insufficiency, severe cardiovascular disease, or psychiatric disorder history
  • Subjects with hearing impairment preventing communication
  • Subjects with a history of long-term sedative or opioid use, or allergies to benzodiazepines, flumazenil, opioids and their antidotes, propofol, eggs, or soy products
  • Subjects with SpO2 < 95% while breathing room air after entering the room

研究组 & 干预措施

propofol-alfentanil

Active Comparator

Sedation using remimazolam-alfentanil

干预措施: propofol-alfentanil (Drug)

remimazolam-alfentanil

Experimental

Sedation using remimazolam-alfentanil

干预措施: remimazolam-alfentanil combination (Drug)

结局指标

主要结局

Incidence of Hypoxia

时间窗: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

SpO₂ between 75% and 89% with duration \<60 seconds

次要结局

  • Incidence of severe hypoxia(Patients will be followed for the duration of hospital stay, an expected average about 2 hours)
  • Incidence of subclinical respiratory depression(Patients will be followed for the duration of hospital stay, an expected average about 2 hours)
  • Proportion of hypoxic correction measures(Patients will be followed for the duration of hospital stay, an expected average about 2 hours)

研究者

发起方
Diansan Su
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Diansan Su

Director of Anesthesiology

Zhejiang University

研究点 (3)

Loading locations...

相似试验

The Efficacy of Remimazolam on Incidence of Hypoxia... | 临床试验